<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084578</url>
  </required_header>
  <id_info>
    <org_study_id>FCCC-03018</org_study_id>
    <secondary_id>CDR0000365460</secondary_id>
    <nct_id>NCT00084578</nct_id>
  </id_info>
  <brief_title>Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder</brief_title>
  <official_title>A Randomized Trial of Celecoxib and Rosiglitazone, Alone and in Combination, in Patients With Early Stage Non-Invasive Bladder Carcinoma Undergoing Cystoscopic Surveillance and in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth and by stopping blood flow to the tumor. Rosiglitazone may help tumor cells&#xD;
      develop into normal bladder cells.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well giving celecoxib together with&#xD;
      rosiglitazone works in treating patients who are undergoing cystoscopic surveillance&#xD;
      (screening) for early-stage noninvasive (carcinoma in situ) carcinoma (cancer) of the bladder&#xD;
      or radical cystectomy for muscle-invasive carcinoma (cancer has spread into the muscle layer&#xD;
      of bladder tissue) of the bladder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether rosiglitazone and celecoxib, administered alone or in combination,&#xD;
           cause changes in the expression of effector molecules, peroxisome proliferator-activated&#xD;
           receptor-γ (PPAR-γ) and cyclo-oxygenase-1 (COX-1), in patients with early-stage&#xD;
           non-invasive carcinoma of the bladder undergoing cystoscopic surveillance or in patients&#xD;
           with muscle-invasive carcinoma of the bladder undergoing radical cystectomy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether these regimens result in changes in the expression of downstream&#xD;
           effector molecules that mediate cellular proliferation and apoptosis in these patients.&#xD;
&#xD;
        -  Determine the relationship between tissue levels of biomarkers of drug effect,&#xD;
           proliferation, and apoptosis and the systemic biomarkers of response to treatment, in&#xD;
           terms of COX-2 activity and the levels of the endogenous PPAR-γ ligand, in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Determine the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Determine the frequency of recurrence and the time to progression in patients undergoing&#xD;
           cystoscopic surveillance.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot, cohort study. Patients are assigned to 1 of 2 cohorts&#xD;
      according to disease stage (Ta, Tis, T1, N0, M0 vs T2-4, NX, M0).&#xD;
&#xD;
        -  Stage 1:&#xD;
&#xD;
             -  Cohort 1: Patients receive oral celecoxib twice daily and oral rosiglitazone once&#xD;
                daily for 1 year in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Cohort 2: Patients receive oral celecoxib twice daily and oral rosiglitazone once&#xD;
                daily for 14 days. Patients then undergo cystectomy.&#xD;
&#xD;
        -  Stage 2: Patients are randomized into 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I:&#xD;
&#xD;
                  -  Cohort 1: Patients receive oral celecoxib twice daily for 1 year in the&#xD;
                     absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
                  -  Cohort 2: Patients receive oral celecoxib twice daily for 14 days. Patients&#xD;
                     then undergo cystectomy.&#xD;
&#xD;
             -  Arm II:&#xD;
&#xD;
                  -  Cohort 1: Patients receive oral rosiglitazone once daily for 1 year in the&#xD;
                     absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
                  -  Cohort 2: Patients receive oral rosiglitazone once daily for 14 days. Patients&#xD;
                     then undergo cystectomy.&#xD;
&#xD;
      Patients in cohort 1 (in both stages) undergo cystoscopic surveillance every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients (20 per cohort in study stage 1; 40 per treatment&#xD;
      arm [20 per cohort in each arm] in study stage 2) will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn due to drug toxicity&#xD;
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone maleate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically and clinically confirmed bladder cancer&#xD;
&#xD;
               -  Cohort 1&#xD;
&#xD;
                    -  Papillary transitional cell carcinoma of the urinary bladder&#xD;
&#xD;
                         -  Stage Ta or T1 (grade 1 or 2), N0, M0 disease&#xD;
&#xD;
                         -  Must have undergone complete transurethral resection of the bladder&#xD;
                            within the past 28 days AND/OR&#xD;
&#xD;
                    -  Carcinoma in situ of the urinary bladder&#xD;
&#xD;
                         -  Stage Tis, N0, M0 disease&#xD;
&#xD;
                         -  Must have undergone biopsy within the past 28 days&#xD;
&#xD;
                    -  No histological and pathological evidence of invasion of the underlying&#xD;
                       muscle (stage T2)&#xD;
&#xD;
               -  Cohort 2&#xD;
&#xD;
                    -  Muscle-invasive papillary transitional cell carcinoma of the urinary bladder&#xD;
&#xD;
                    -  Stage T2-4, NX, M0 disease&#xD;
&#xD;
                    -  Intending to undergo radical cystectomy&#xD;
&#xD;
                    -  Must have had an upper tract (ureter and renal pelvic) evaluation by&#xD;
                       intravenous pyelogram, CT scan, or MRI that proved normal within the past&#xD;
                       year&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 4,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT &lt; 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 3 years except non-invasive bladder cancer,&#xD;
             adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  No history of uncontrolled peptic ulcer disease&#xD;
&#xD;
          -  No history of unexplained hypoglycemia&#xD;
&#xD;
          -  No known sensitivity to celecoxib or rosiglitazone&#xD;
&#xD;
          -  No allergy to sulfonamides&#xD;
&#xD;
          -  No history of asthma, urticaria, or allergic reaction after taking aspirin or other&#xD;
             NSAIDs&#xD;
&#xD;
          -  No underlying uncontrolled medical illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 months since prior intravesical BCG&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior intravesical or systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent insulin&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior use of non-steroidal anti-inflammatory drugs (NSAIDs)&#xD;
             (including COX-2 inhibitors) for more than 3 consecutive days except low-dose (81 mg)&#xD;
             aspirin&#xD;
&#xD;
          -  No concurrent beta-blockers&#xD;
&#xD;
          -  No concurrent NSAIDs&#xD;
&#xD;
          -  No other concurrent oral hypoglycemic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

